Results 191 to 200 of about 18,455 (220)

Peptide Receptor Radionuclide Therapy for Sarcoidosis [PDF]

American Journal of Respiratory and Critical Care Medicine, 2016
Lapa, Constantin, Grigoleit, Götz Ulrich, Hänscheid, Heribert, Klinker, Erdwine, Jung, Pius, Herrmann, Ken, Schirbel, Andreas, Böck, Markus, Buck, Andreas K., Pelzer, Theo   +9 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Dosimetry for Peptide Receptor Radionuclide Therapy

2012
For over more than a decade, the progressive evolution of Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of tumors expressing somatostatin receptors has been constantly challenging—and challenged by—dosimetry. The improvements reached in the therapeutical applications of 90Y- and 177Lu- radiolabeled peptides are considerable, and new ...
Marta Cremonesi, Christiane Schuchardt
openaire   +1 more source

Peptide Receptor Radionuclide Therapy–Induced Gitelman-like Syndrome

American Journal of Kidney Diseases, 2017
Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic.
Aurelio, Negro, Giovanni M, Rossi, Davide, Nicoli, Annibale, Versari, Enrico, Farnetti, Rosaria, Santi, Stefano, De Pietri   +6 more
openaire   +2 more sources

Renal Function Assessment During Peptide Receptor Radionuclide Therapy

Seminars in Nuclear Medicine, 2016
Theranostics labeled with Y-90 or Lu-177 are highly efficient therapeutic approaches for the systemic treatment of various cancers including neuroendocrine tumors and prostate cancer. Peptide receptor radionuclide therapy (PRRT) has been used for many years for metastatic or inoperable neuroendocrine tumors.
Belkis, Erbas, Murat, Tuncel
openaire   +2 more sources

Neuroendocrine tumors. Peptide receptor radionuclide therapy.

Best practice & research. Clinical endocrinology & metabolism, 2007
Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues is an emerging and convincing treatment modality for patients with unresectable, somatostatin-receptor-positive neuroendocrine tumours. Using radiolabelled somatostatin analogues for imaging became the gold standard for staging of neuroendocrine tumours.
Flavio, Forrer, Roelf, Valkema, Dik J, Kwekkeboom, Marion, de Jong, Eric P, Krenning   +4 more
openaire   +1 more source

Peptide receptor radionuclide therapy

2010
[No abstract available]
openaire   +1 more source

Receptor-Targeted Radionuclide Imaging (RTRI) and Peptide Receptor Radionuclide Therapy (PRRT)

2019
Increased amount of folate is needed for cells under rapid proliferation such as cancer cells. Folate receptors (FRs) are shown to be overexpressed on the surface of tumor cells under low folate conditions and viewed as tumor-associated antigen. The FRs could specifically bind folate and folate conjugates with very high affinity and then transport ...
Weidong Yang, Cheng Wang, Gang Huang
openaire   +1 more source

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Victoria Metaxa, Elie Azoulay   +2 more
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Rujul Parikh
exaly